Bristol-Myers Squibb Company v Apotex Pty Ltd

The case of Bristol-Myers Squibb Company v Apotex Pty Ltd involved an application by Bristol-Myers Squibb Company to amend its patent under sections 102(1) and 102(2) of the Patents Act 1990 (Cth). The application was made in the context of pending proceedings, necessitating the use of section 105 of the Act, which allows the Court to direct the Commissioner to amend a patent. The Commissioner did not oppose the amendments, and no other party had come forward to do so either. The central legal issues revolved around whether the proposed amendments to the patent were allowable under the Act, specifically considering whether they would claim matter not in substance disclosed in the specification as filed or whether they would cause a claim to fall outside the scope of the claims before amendment.

The court considered the statutory provisions and case law to determine the allowable scope of amendments. It noted that an amendment is not allowable if it claims matter not in substance disclosed in the specification as filed or if it causes a claim to fall outside the scope of the claims before amendment. The court also emphasised the importance of the phrase "as a result of the amendment" in understanding the scope and effect of the proposed changes. The court concluded that the proposed amendments were allowable under the Act as they did not claim matter not in substance disclosed in the specification as filed and did not cause a claim to fall outside the scope of the claims before amendment.

The court ordered that the second applicant inform the court by a specified date if it wished to be heard further on the admissibility of the proposed claims or if it wished to propose further limitations. The matter was then listed for further directions.